AssetMark Inc
KRYS icon

AssetMark Inc’s Krystal Biotech KRYS Stock Holding History

AssetMark Inc’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.74M Buy
5,238
+1,499
+40% +$519K ﹤0.01% 987
2026
Q2 		$1.39M Buy
3,739
+582
+18% +$174K ﹤0.01% 1027
2026
Q1 		$816K Buy
+3,157
New +$840K ﹤0.01% 1077
2025
Q1 		– Sell
-1
Closed -$157 – 2697
2024
Q4 		$157 Buy
+1
New +$177 ﹤0.01% 2500

Other funds holding KRYS

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return

AssetMark Inc's KRYS Position: Q3 2026 in Review

AssetMark Inc increased its Krystal Biotech (KRYS) stake by 40% in Q3 2026, buying an estimated $519K and bringing the position to 5,238 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #987.

AssetMark Inc first reported a position in KRYS in Q4 2024 and has held it in 4 quarters since. 161 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • AssetMark Inc held 5,238 shares of Krystal Biotech worth $1.74M as of Q3 2026.
  • AssetMark Inc bought 1,499 Krystal Biotech shares in Q3 2026, an estimated $519K.
  • Krystal Biotech made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #987 holding.
  • AssetMark Inc first reported a position in Krystal Biotech in Q4 2024 and has held it in 4 quarters since.
  • 161 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.